ABSTRACT. Growth arrest and DNA damage-inducible protein 45 (GADD45) plays an important role in suppressing multistep carcinogenesis. In this report, we describe the isolation of the complete wild-type feline GADD45 cDNA from feline tissues. Expression of feline GADD45 mRNA was detected in the liver, spleen, kidney, lung, and testis. The predicted amino acid sequences encoded by the fulllength feline GADD45 cDNA display sequence homology with those from other vertebrates, and as in the case of human GADD45, cell growth suppression was observed by ectopic expression of feline GADD45. However, no mutations were detected by sequence analysis of feline GADD45 in several feline lymphoma cell lines, indicating that the GADD45 mutation might be uncommon in feline oncogenesis. KEY WORDS: feline, GADD45, P53.
In response to DNA damage, mammalian cells arrest at the transitions from the G1 to the S phase (G1-S checkpoint) or from the G2 to the M phase (G2-M checkpoint) [11] . Cell cycle arrest at these checkpoints prevents DNA replication and mitosis after the DNA is damaged. Inactivation of these cell cycle checkpoints results in genomic instability, which is closely associated with cell transformation and tumorigenesis. In addition, disruption of the normal cell cycle controlling machinery often has drastic consequences on therapeutic sensitivity [5, 12, 17, 24] .
The tumor suppressor p53 gene plays a critical role in control of G1-S arrest. Following DNA damage, P53 transcriptionally up-regulates p21/Waf1 [4] , which is one of the P53-downstream genes and a potent cell cycle-dependent inhibitor. Subsequently, the induced p21/Waf1 forms complexes with Cdk-cyclin and inhibits its activity, which in turn transiently arrest cells at the G1-S transition [10, 25, 32] . P53 has also been implicated in the control of the G2-M checkpoint. Introduction of P53 into p53-deficient human fibroblasts results in both G1-S and G2-M arrest [1, 27] . In addition, the 14-3-3 protein, which blocks Cdc25 activity and arrests cells at the G2-M transition, has been demonstrated to be the product of one of the P53 downstream genes [13] . Functional inactivation of P53 is a very common event in many types of human cancers [8] and is a key step in oncogenesis [9] . Moreover, p53 mutations have been shown not only in human tumors, but also in feline tumors [19, 22] .
Growth arrest and DNA damage-inducible gene 45 (GADD45), P53-regulated genes, and DNA damage-inducible genes have been found to play an important role in the G2-M checkpoint in response to certain types of DNA damaging agents [15, 16, 31, 34] . GADD45 was initially identified on the basis of its rapid transcriptional induction after UV irradiation [7] . Some experiments have implicated GADD45 in DNA replication, DNA repair, G1 progression, G2/M checkpoint control, apoptosis, and regulation of signal transduction [6, [28] [29] [30] [31] . GADD45 displays a complex array of physical interactions with other proteins involved in these processes. The role of GADD45 in maintaining genomic stability has been demonstrated by a recent finding that mouse embryonic fibroblasts derived from GADD45-null mice exhibit aneuploidy, chromosomal aberrations, gene amplification, and centrosome amplification-a phenotype strikingly similar to that of cells derived from p53-null mice [14] .
Recently, Miki et al. reported that chromosome instability and consequent centrosome amplification were observed in feline lymphoma cell lines, although they showed a wildtype p53 status [19] . Based on this information, we examined whether GADD45 mutations under certain conditions could substitute for the p53 mutations in feline oncogenesis. For example, in the presence of wild-type p53, loss of GADD45 function (by mutation) should give a similar phenotype to that caused by P53 inactivation. In the present study, we cloned the complete wild-type feline GADD45 (fGADD45) cDNA, and then performed mutation analysis of the fGADD45 cDNA in feline lymphoma cell lines with a known p53 status [19] .
For isolation of feline fGADD45 cDNA, total RNAs were prepared from 20 mg of fresh feline tissues (liver, spleen, kidney, lung, and testis) using the RNeasy Mini Kit . Feline β-actin cDNA was also amplified as an internal control. The amplified products were screened on 1.8% agarose gel (Agarose S, Nippon Gene, Tokyo, Japan) and stained with 10 µg/ml of ethidium bromide (Sigma, St.
Louis, MO, U.S.A.). A DNA fragment of approximately 550 bp, corresponding to the predicted full-length fGADD45 cDNA, was detected in each sample (Fig. 1) . The amplified DNA band was extracted from the agarose gel using a QIAquick ® Gel Extraction Kit (QIAGEN, Studio City, CA, U.S.A.). For direct sequence analysis, fluorescence labeled dideoxynucleotide technology was used for DNA sequencing reactions (Perkin-Elmer, Applied Biosystems Division, Foster City, CA, U.S.A.). Samples were then sequenced using a Perkin-Elmer ABI Prism 377 automated DNA sequencer. The nucleotide sequence of each fragment was determined for both DNA strands in opposite direction using three independent PCR products. The full-length fGADD45 cDNA contained an open reading frame of 495 bases encoding 165 amino acids (GenBank Accession No. AB176962). No nucleotide mutations were detected among the tissue specimens. The phylogenic relationships among the various homologs of GADD45 amino acid were evaluated with the ClustalW program, and resulting molecular phylogenetic tree is shown in Fig. 2A . The predicted amino acid sequence of fGADD45 was aligned with its human, cow, mouse, rat, xenopus, and zebrafish counterparts (Fig.  2B) . The amino acid sequence identity by FASTA program showed high levels of homology as follows: human (99.4%), cow (98.8%), mouse (92.7%), rat (93.9%), xenopus (68.5%), and zebrafish (70.9 %), respectively.
Cell growth suppression has been observed by ectopic expression of human GADD45 in tumor cell lines [35] . Thus, we performed a colony formation assay to investigate whether fGADD45 functions as a cell growth suppressor. The coding sequences of fGADD45 were amplified by PCR, as described above, using forward primer (F2), 5'-GCAAGCTTATGACTTTGGAGG-3' (nt 1 to 13 in fGADD45 cDNA) and reverse (R2) primers, 5'-ATGATATCTCACCGTTCAGGGAG-3' (nt 498 to 484 in fGADD45 cDNA), with the HindIII or EcoRV restriction sites, respectively (GenBank Accession No. AB176962). The amplified products were digested with HindIII and EcoRV restriction enzymes (New England Biolabs, Beverly, MA, U.S.A.) and inserted into the pcDNA3.1(+) mammalian expression vector (pcDNA-fGADD45) (Invitrogen, Carlsbad, CA, U.S.A.). In each experiment, the growing feline mammary gland tumor (FRM) cells and Crandell feline kidney (CRFK) cells were seeded in triplicate at a density of 1 × 10 6 cells/35-mm dish. Twenty-four hours later, these cells were transfected using Lipofectamine TM 2000 (Invitrogen, Carlsbad, CA, U.S.A.) with 4 µg of pcDNA-fGADD45 along with 0.2 µg of plasmid encoding a hygromycin-resistant gene (pHEBO) as a selection marker. As a control, cells were transfected with pcDNA3.1(+) without an insert (Vector). Twenty-four hours after transfection, cells were replated in 100-mm diameter dishes and 100 µg/ ml of hygromycin (Sigma, St. Louis, MO, U.S.A.) was added. The medium was replaced every 4 days with fresh medium containing hygromycin. On the 14th day after transfection, the cells were fixed with 10 % formalin (Falma, Tokyo, Japan) and stained with Giemsa stain (KPL, Gaithersburg, MD, U.S.A.). Selected colony counting showed that introduction of fGADD45 resulted in substantial cell growth suppression (FRM cells; 81.3 ± 19.2, CRFK cells; 79.3 ± 8.5, means ± standard deviations from triplicate (Fig.  3A) . Figure 3B shows the relative plating efficiency to fGADD45 transfected cells. The induction of fGADD45 suppressed cell growth by 39.0% for the FRM cells and 35.7% for the CRFK cells. Using RT-PCR, the transfected cells were also tested to determine whether the fGADD45 was correctly expressed. Strong expression of fGADD45 was detected in the pcDNA-fGADD45-transfected cells; however, slight expression was found in pcDNA3.1(+)-transfected cells similar to that observed in non-transfected cells (data not shown). We next conducted mutation analysis of fGADD45 in feline lymphoma cell lines. We selected five feline lymphoma cell lines with a known p53 status to search for mutations [19] . Also, the phenotypes of these cell lines were all of T-cell origin (R-96 and KO-1 [unpublished observation, Okuda M], FL-74 [18] , FT-1 [20] , and 3201 [26] ). The p53 status and phenotype of these cell lines are listed in Table 1. RT-PCR and sequence analysis were performed as described above. However, no fGADD45 mutations were observed in any of the cell lines analyzed (Table 1) .
In this study, we cloned the complete fGADD45 cDNA and examined fGADD45 mRNA expression in several normal feline tissues. Expression of fGADD45 mRNA was detected in all the examined normal feline tissues (liver, spleen, kidney, lung, and testis) (Fig. 1) . Notably, the fGADD45 sequence displays sequence homology with GADD45 amino acid sequences from other vertebrates. Cell growth suppression, which has been shown as a one of the functions of human GADD45 [35] , was observed following the introduction of fGADD45 in the feline mammary gland tumor (FRM) cells and Crandell feline kidney (CRFK) cells (Fig. 3) . Thus, these results suggest that fGADD45 might have the same function as that of other higher vertebrates.
We also examined mutation analysis of fGADD45 in five feline lymphoma cell lines with a known p53 status (R-96, KO-1, FL-74, FT-1, and 3201 cell lines). However, no fGADD45 mutations were observed in any of the cell lines analyzed ( Table 1 ). The data presented in this work indicates that mutation in the fGADD45 coding region is not a common event in feline oncogenesis. Support for this comes from the only other reported analyses of the GADD45 gene in human cancer. Blaszyk et al. and Campomenosi and Hall investigated the human GADD45 status in a panel of primary tumor samples or tumor cell lines; however, no mutations were observed in the samples and tumor cell lines analyzed [2, 3] . While GADD45 inactivation and p53 inactivation are phenocopies in the artificial setting of gene targeting in mice [14] , it would appear that GADD45 might not be a critical target for inactivation in the same manner as p53. A similar observation has been reported for feline p21/Waf1, which is another P53 target gene with potent effects on cells [4] but in which mutation is a rare event in feline lymphoma [21] . Centrosome amplification, consequent abnormal mitosis, and aneuploidy were observed in the feline lymphoma cell lines used above; however, p53 mutation and MDM2 overexpression, which are the causes of centrosome amplification, did not play a major role [19] . Thus, factors other than GADD45 mutation, p53 mutation, and MDM2 overexpression might be important in feline oncogenesis. 
